Thailand Adopts Policy To Restrict Use Of A/H1N1 Antivirals
This article was originally published in PharmAsia News
Executive Summary
Thailand's Public Health Ministry has put in place plans to impose restrictions on the use of antiviral drugs for treating the A/H1N1 flu virus. The restrictions are intended to avoid the virus developing into a drug-resistant version as a result of over-prescribing. Under the plan, the drugs are to be prescribed only after laboratory tests confirm a patient has A/H1N1. Until the new guidelines, the ministry had allowed Roche's Tamiflu (oseltamivir) to be provided to patients who had a high fever and had recently returned from countries where infections were reported. (Click here for more
You may also be interested in...
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.
Ratio Therapeutics On BMS Investment, Radiopharma R&D Trends, AI Use
The CEO and CSO of radiopharmaceutical company Ratio Therapeutics, which now has Bristol Myers Squibb as an investor, talk about Ratio’s R&D platforms, use of AI, an independent FAP-targeted asset and trends in radiopharma research such as combining other modalities like ADCs, in this podcast interview with Scrip
With One Launch Under Way, SpringWorks Ramps Up For A Second
The company initiated a rolling submission with the US FDA for mirdametinib, a MEK inhibitor that is poised to be its second commercial product for a rare disease.